OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.880
+0.100 (5.62%)
At close: Aug 13, 2025, 4:00 PM
1.860
-0.020 (-1.06%)
Pre-market: Aug 14, 2025, 9:21 AM EDT
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OS Therapies Incorporated
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 1, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Paul Romness |
Contact Details
Address: 115 Pullman Crossing Road, Suite 103 Grasonville, Maryland 21638 United States | |
| Phone | 410-297-7793 |
| Website | ostherapies.com |
Stock Details
| Ticker Symbol | OSTX |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001795091 |
| ISIN Number | US68764Y2072 |
| Employer ID | 82-5118368 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert G. Petit Ph.D. | Chief Medical Officer and Chief Scientific Officer |
| Jack Doll | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | EFFECT | Notice of Effectiveness |
| Aug 8, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 4, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 16, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 14, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 8-K | Current Report |
| Jun 6, 2025 | EFFECT | Notice of Effectiveness |
| May 28, 2025 | UPLOAD | Filing |